MedTrace Logo

Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease

NCT07416461 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2026-02-18

No results posted yet for this study

Summary

The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5. Eligible participants residing in the Kisantu Health Zone (DRC) and presenting fever are enrolled in healthcare facilities and tested for malaria and iNTS. Using a case-control (test-negative) design, the researchers will look at the malaria vaccination status of participants with and without iNTS infection to determine if the malaria vaccine protects against iNTS.

Conditions

  • Invasive Non-Typhoidal Salmonella Disease
  • Malaria
  • Malaria Vaccine

Interventions

BIOLOGICAL

R21/Matrix-M malaria vaccine

R21/Matrix-M malaria vaccination was introduced by DRC Ministry of Public Health in the Expanded Program on Immunizations on 29th of October 2024. Children aged 6 months to 24 months are eligible to receive the vaccine. Vaccination follows a 4 doses schedule: a first dose administered between 6 and 11 months of age, a second dose one month after the first dose, a third dose one month after the second dose and a booster dose seven months after the third dose.

Sponsors & Collaborators

  • International Vaccine Institute

    lead OTHER

Principal Investigators

  • Octavie Lunguya · Institut National de Recherche Biomedicale

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-27
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Democratic Republic of the Congo

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07416461 on ClinicalTrials.gov